Associations of HbA1c with the timing of C-peptide responses during the oral glucose tolerance test at the diagnosis of type 1 diabetes.
C-peptide
HbA1c
OGTT
glycemia
type 1 diabetes
Journal
Pediatric diabetes
ISSN: 1399-5448
Titre abrégé: Pediatr Diabetes
Pays: Denmark
ID NLM: 100939345
Informations de publication
Date de publication:
06 2019
06 2019
Historique:
received:
16
10
2018
revised:
23
01
2019
accepted:
04
03
2019
pubmed:
21
3
2019
medline:
24
3
2020
entrez:
21
3
2019
Statut:
ppublish
Résumé
In new onset type 1 diabetes (T1D), overall C-peptide measures such as area under the curve (AUC) C-peptide and peak C-peptide are useful for estimating the extent of β-cell dysfunction, and for assessing responses to intervention therapy. However, measures of the timing of C-peptide responsiveness could have additional value. We assessed the contribution of the timing of C-peptide responsiveness during oral glucose tolerance tests (OGTTs) to hemoglobin A1c (HbA1c) variation at T1D diagnosis. We analyzed data from 85 individuals <18 years with OGTTs and HbA1c measurements at diagnosis. Overall [AUC and peak C-peptide] and timing measures [30-0 minute C-peptide (early); 60 to 120 minute C-peptide sum-30 minutes (late); 120/30 C-peptide; time to peak C-peptide] were utilized. At diagnosis, the mean (±SD) age was 11.2 ± 3.3 years, body mass index (BMI)-z was 0.4 ± 1.1, 51.0% were male. The average HbA1c was 43.54 ± 8.46 mmol/mol (6.1 ± 0.8%). HbA1c correlated inversely with the AUC C-peptide (P < 0.001), peak C-peptide (P < 0.001), early and late C-peptide responses (P < 0.001 each), and 120/30 C-peptide (P < 0.001). Those with a peak C-peptide occurring at ≤60 minutes had higher HbA1c values than those with peaks later (P = 0.003). HbA1c variance was better explained with timing measures added to regression models (R These findings show that the addition of timing measures of C-peptide responsiveness better explains HbA1c variation at diagnosis than standard measures alone.
Sections du résumé
BACKGROUND
In new onset type 1 diabetes (T1D), overall C-peptide measures such as area under the curve (AUC) C-peptide and peak C-peptide are useful for estimating the extent of β-cell dysfunction, and for assessing responses to intervention therapy. However, measures of the timing of C-peptide responsiveness could have additional value.
OBJECTIVES
We assessed the contribution of the timing of C-peptide responsiveness during oral glucose tolerance tests (OGTTs) to hemoglobin A1c (HbA1c) variation at T1D diagnosis.
METHODS
We analyzed data from 85 individuals <18 years with OGTTs and HbA1c measurements at diagnosis. Overall [AUC and peak C-peptide] and timing measures [30-0 minute C-peptide (early); 60 to 120 minute C-peptide sum-30 minutes (late); 120/30 C-peptide; time to peak C-peptide] were utilized.
RESULTS
At diagnosis, the mean (±SD) age was 11.2 ± 3.3 years, body mass index (BMI)-z was 0.4 ± 1.1, 51.0% were male. The average HbA1c was 43.54 ± 8.46 mmol/mol (6.1 ± 0.8%). HbA1c correlated inversely with the AUC C-peptide (P < 0.001), peak C-peptide (P < 0.001), early and late C-peptide responses (P < 0.001 each), and 120/30 C-peptide (P < 0.001). Those with a peak C-peptide occurring at ≤60 minutes had higher HbA1c values than those with peaks later (P = 0.003). HbA1c variance was better explained with timing measures added to regression models (R
CONCLUSIONS
These findings show that the addition of timing measures of C-peptide responsiveness better explains HbA1c variation at diagnosis than standard measures alone.
Identifiants
pubmed: 30891858
doi: 10.1111/pedi.12845
pmc: PMC6655420
mid: NIHMS1041777
doi:
Substances chimiques
Blood Glucose
0
C-Peptide
0
Glycated Hemoglobin A
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
408-413Subventions
Organisme : NIDDK NIH HHS
ID : U01 DK085476
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK061010
Pays : United States
Organisme : NIAID NIH HHS
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001863
Pays : United States
Organisme : BLRD VA
ID : I01 BX001733
Pays : United States
Organisme : NIDDK NIH HHS
ID : P30 DK097512
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA076292
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK103282
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK061042
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK085509
Pays : United States
Organisme : NIDDK NIH HHS
ID : UC4 DK117009
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK093954
Pays : United States
Organisme : NIDDK NIH HHS
ID : P30 DK017047
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK085466
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK103153
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK061058
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK106984
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK085499
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK107013
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK103266
Pays : United States
Organisme : NIDDK NIH HHS
ID : UC4 DK106993
Pays : United States
Organisme : NIDDK NIH HHS
ID : P30 DK045735
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK107014
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK106994
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK061034
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK085461
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK103180
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK085465
Pays : United States
Informations de copyright
© 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
Pediatr Diabetes. 2017 Dec;18(8):794-802
pubmed: 28127835
Diabetes. 2012 Jun;61(6):1331-7
pubmed: 22618768
Diabetes Technol Ther. 2015 Sep;17(9):649-56
pubmed: 26317880
Diabetes Care. 2015 Jan;38 Suppl:S8-S16
pubmed: 25537714
Diabetes Care. 2009 Feb;32(2):301-5
pubmed: 19017769
Diabetologia. 1987 Apr;30(4):208-13
pubmed: 3297896
Diabetes Care. 2003 Mar;26(3):832-6
pubmed: 12610045
N Engl J Med. 2002 May 30;346(22):1685-91
pubmed: 12037147
Transplantation. 2009 Mar 15;87(5):689-97
pubmed: 19295313
Pediatr Diabetes. 2018 May;19(3):403-409
pubmed: 29171129